Clinical Trial Update: Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating RUCONEST for improving neurological symptoms in post-COVID-19 infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-viral Fatigue Syndrome

Drugs mentioned

• Ruconest (conestat alfa)

Snippet

Sponsor: IMMUNOe Research Centers | Conditions: Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder) | Phase 2 | Status: COMPLETED